Cardiovascular diseases are among the leading causes of death globally. It is estimated that approximately 3.5 million people die from cardiovascular diseases annually in China, ranking first among all disease categories. Cardiovascular and cerebrovascular diseases often have insidious onset, long courses, and are prone to recurrent episodes. Severe adverse events such as myocardial infarction and stroke directly threaten patients' lives, imposing extremely heavy healthcare burdens on families and society.
Guangzhou Evidence-Based Medicine has a professional, patient-centered clinical trial team and extensive execution management experience in the cardiovascular field. Addressing operational pain points such as stringent subject screening, commonly set washout and run-in periods leading to high screening failure rates, we have established efficient precision screening and subject management mechanisms. We also have an extensive network of collaborative hospitals and maintain close partnerships with top experts in the cardiovascular field.
With a professional and efficient service system and a comprehensive operational network, Guangzhou Evidence Based Medicine is committed to providing tailored one-stop traditional Chinese medicine research and development full industry chain service solutions for every customer, promoting traditional Chinese medicine to the world and safeguarding the health of more people.
